Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries

Flexilev® in OraFID® ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more frequent doses. Flexilev ®in OraFID ®ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more...

OSLO, Norway, 13/08/2025 (informazione.news - comunicati stampa - salute e benessere)

Flexilev in OraFID ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more frequent doses.

OraFID is a unique, patented, fully mechanical medical device that dispenses precise quantities of minitablets with just a few of twists of the hands.

The launch in the Nordic markets is still anticipated in October 2025 .

Kathrine Gamborg Andreassen , CEO, Navamedic Lars Hjarrand, CFO, Navamedic
Mobile: +47 951 78 680 Mobile: +47 917 62 842
E-mail: kathrine@navamedic.com E-mail: lars.hjarrand@navamedic.com

For more information, please visit
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/navamedic-asa/r/navamedic-asa--national-approvals-of-flexilev--in-orafid--granted-across-all-nordic-countries-,c4217408

 

View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-national-approvals-of-flexilev-in-orafid-granted-across-all-nordic-countries-302528798.html